...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Predictors of aripiprazole treatment continuation in hospitalized patients.
【24h】

Predictors of aripiprazole treatment continuation in hospitalized patients.

机译：住院患者阿立哌唑治疗持续时间的预测指标。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Aripiprazole is a second-generation antipsychotic that is increasingly prescribed in a variety of psychiatric disorders. The goal of this study was to investigate patient and treatment factors associated with aripiprazole treatment continuation on hospital discharge in psychiatric inpatients. METHOD: This was a retrospective cohort analysis of patients admitted to a psychiatric hospital between January 1, 2003, and June 30, 2006, and treated with aripiprazole. The goal was to determine factors associated with continuation of aripiprazole throughout the hospital stay and on discharge from the hospital. Covariates assessed included patient demographics, prior psychiatric hospitalizations, diagnoses, prior antipsychotic use, and concomitant psychotropic medications. Aripiprazole-specific covariates were starting and maximum dose and dose titration pattern. Diagnoses were identified using ICD-9-CM codes. RESULTS: There were 1957 aripiprazole-treated patients included in this study, and 1573 (80%) continued aripiprazole treatment at the time of hospital discharge. Median starting doses were lower (5 mg/day) for younger and older patients, and patients with psychotic disorders received higher doses than other patients. Approximately 58% of patients had at least 1 aripiprazole dose titration while hospitalized, and most (73%) of those patients had a dose titration within 3 days of admission. Predictors of treatment continuation in this broad patient population were younger age, a diagnosis of bipolar or major depressive disorder, higher maximum aripiprazole doses, and upward dose titration within 3 days of admission. Patients receiving concomitant anticholinergics or antipsychotics were less likely to continue treatment as were those receiving aripiprazole at the time of hospitalization. CONCLUSION: In this acute inpatient psychiatric setting, continuation of aripiprazole treatment on discharge was achieved in most patients. Demographic, diagnostic, and treatment factors predicting aripiprazole treatment effectiveness were identified.
机译：目的：阿立哌唑是第二代抗精神病药，越来越多地用于各种精神疾病。这项研究的目的是调查精神病住院患者出院后继续使用阿立哌唑治疗的相关患者和治疗因素。方法：这是一项回顾性队列分析，分析了2003年1月1日至2006年6月30日期间接受阿立哌唑治疗的精神病医院的患者。目的是确定在整个住院期间和出院后阿立哌唑持续使用的相关因素。评估的协变量包括患者的人口统计学资料，先前的精神病院住院治疗，诊断，先前的抗精神病药物使用以及相关的精神药物。阿立哌唑特异性协变量是起始剂量，最大剂量和剂量滴定模式。使用ICD-9-CM代码识别诊断。结果：本研究包括1957例接受阿立哌唑治疗的患者，出院时继续接受1573例（80％）阿立哌唑治疗。对于年轻和老年患者，中位起始剂量较低（5 mg /天），患有精神病的患者比其他患者接受更高的剂量。大约58％的患者在住院期间进行了至少1剂阿立哌唑剂量滴定，其中大多数（73％）患者在入院后3天内进行了剂量滴定。在这一广泛的患者人群中，继续治疗的预测因素是年龄较小，双相或重度抑郁症的诊断，阿立哌唑的最大剂量较高以及入院后3天内剂量增加。接受抗胆碱药或抗精神病药物治疗的患者与住院期间接受阿立哌唑的患者相比，继续治疗的可能性较小。结论：在这种急性住院精神病患者中，大多数患者在出院时仍继续使用阿立哌唑治疗。确定了预测阿立哌唑治疗效果的人口统计学，诊断和治疗因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号